ClinicalTrials.gov
public full text
Public Domain
PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of PA-824 at 200, 600, 1000 and 1200 mg per day in adult patients with newly diagnosed, uncomplicated, smear positive tuberculosis. A control group will receive standard TB treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)#894455
- Shortening Treatment by Advancing Novel Drugs#1153608
- Effects of pyrazinamide and/or ethambutol resistance on Tuberculosis treatment outcome by whole genome sequencing, South Africa 2020 – 2022#447668
- Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis#872801
- Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB#813717
Record · ID 861002
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive